Figure 11.

Intracoronary adenoviral S100A1 gene delivery rescues contractile dysfunction in vivo. (A_F) Representative corresponding Nomarski and GFP-fluorescence images from midventricular cryosections of nonfailing (A and B) and AdS100A1- (C and D) and AdGFP-treated (E and F) failing myocardium. Magnification, ×10. (G) Cardiac S100A1 gene transfer reconstitutes S100A1 protein levels in failing myocardium in vivo. Representative Western blot of S100A1, CSQ and GFP expression in sham-OP nonfailing, saline-treated failing, and adenovirus-treated (AdGFP/AdS100A1) failing myocardium. (H_L) Restoration of basal cardiac contractile performance after AdS100A1 gene transfer in vivo. (M_O) Preserved gain-in-function of AdS100A1-treated failing hearts in vivo after isoproterenol stimulation. Saline- and AdGFP-treated failing hearts displayed no significant difference in functional parameters and were combined to heart failure control group (HF-control; n = 14). Data were obtained in isoflurane-anesthetized animals 7 days after intracoronary gene transfer or saline injection. Sham-OP; n = 7, HF-AdS100A1; n = 7. *P < 0.05 HF-AdS100A1 vs. HF control. BW, body weight.